Home Innovation That Matters

Innovation That Matters

Inside Perspectives on Cancer Immunotherapy: An Interview with TCR2 Therapeutics CEO Garry Menzel

TCR2 Therapeutics CEO Garry Menzel, Ph.D., says immunotherapies represent “a new golden age” of medicines to treat cancer and much of the excitement surrounds their potential to cure patients, but he cautions they are not “a panacea.” The Cambridge, Mass.–based company has developed an approach...

Gut Instinct: Leveraging the Microbiome and Human Immune System to Dramatically Transform Medicine

By Hui Cai, Vice President of Corporate Alliances and Head of Corporate Communications, WuXi AppTec The drive behind Simba Gill’s success comes from having a deep passion for science, following opportunities regardless of geographical boarders, as well as surrounding himself with talented people. He is also...

Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato

Shawn Iadonato and his team at Kineta are hoping to play a big role in the next frontier of immuno-oncology by making cold tumors hot and by closing the big gap of unmet needs for patients. The Seattle, WA.-based translational research company has a...

Improving the Odds in Cancer With First-Time Immunotherapies

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) With a strong belief that precision medicine is the future backbone of medicine, combined with advancements in the cancer immunotherapy field, and a unique platform, four-year-old Cambridge, Mass. biotech player Jounce Therapeutics is...

Inside Perspectives on Immunotherapy: An Interview with Advaxis CEO Daniel O’Connor

Advaxis Immunotherapies, led by President and CEO Daniel O’Connor, is developing a promising and versatile approach to immuno-oncology with its Listeria monocytogenes (Lm) antigen delivery system. Lm Technology™ shows the immune system how to identify and target tumors, weakens tumor defense mechanisms, and triggers...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities...